Neurocrine Biosciences Inc is a biopharmaceutical company based in San Diego, California, focusing on developing treatments for neurological, neuroendocrine, and neuropsychiatric disorders. Its portfolio includes INGREZZA for tardive dyskinesia, ALKINDI for adrenal insufficiency, and several products for conditions like Huntington’s disease, endometriosis, and uterine fibroids. The company is also advancing a range of candidates for conditions such as developmental and epileptic encephalopathy, major depressive disorder, and schizophrenia, among others. Neurocrine Biosciences maintains collaborations with various pharmaceutical companies to enhance its research and development efforts.
Crinetics Pharmaceuticals (NASDAQ:CRNX | CRNX Price Prediction) shares have climbed 99% just this week, from $42.03 at Monday’s close, to $83.54 earlier today. The simple reason: Vertex Pharmaceuticals (NASDAQ:VRTX) agreed to acquire…
Pre-Market Stock Futures: Futures are trading higher this morning after a dreadful day to start the trading week. Various reasons were cited for the risk-off bias on Monday, but the tariff situation,…
Pre-Market Stock Futures: The futures are trading lower on Thursday after investors and traders tapped the brakes on the 2026 new year rally, as only the Nasdaq was able to grind out…
Neurocrine Biosciences (NASDAQ: NBIX | NBIX Price Prediction) delivered a decisive earnings beat in Q3, posting adjusted EPS of $2.17 against expectations of $1.62 and revenue of $794.9M versus $761.4M consensus. The…
Joel South If you work in the biotech industry, you might know the name Alex Denner. If not, his name probably doesn’t ring a bell. Denner is the CEO and CIO of Sarissa Capital…
Market pullbacks can make nervous investors leery of investing in industries that are more speculative. Wall Street still has big expectations for Viking Therapeutics.
Thursday's top analyst upgrades and downgrades included Best Buy, Carnival, Caterpillar, Centene, ChargePoint, Foot Locker, Hewlett Packard Enterprise, Palo Alto Networks, PDD, Peloton Interactive, Realty Income, Sunrun, Texas Instruments and UDR.
Thursday's top analyst upgrades and downgrades included Advanced Micro Devices, Caesars Entertainment, Caterpillar, CrowdStrike, Crown Castle, Electronic Arts, Estee Lauder, KeyCorp, Match, Norwegian Cruise Line, Sirius XM, SoFi Technologies and TG Therapeutics.
Tuesday's top analyst upgrades and downgrades included American Express, Apple, AppLovin, Conagra Brands, D.R. Horton, Estee Lauder, Juniper Networks, Livent, Microsoft, Netflix, Nvidia, Shopify, Tesla, and Twilio.
Friday's top analyst upgrades and downgrades included American Express, Aptiv, BorgWarner, First Horizon, Keurig Dr Pepper, Meta Platforms, MGIC Investment, Simon Property Group and Teva Pharmaceutical Industries.
Friday's top analyst upgrades and downgrades included Builders FirstSource, CVS Health, DHT, Incyte, McDonald's, Newell Brands, PacWest Bancorp, Wingstop and ZoomInfo Technologies.
Wednesday's top analyst upgrades and downgrades included Annaly Capital Management, Capri, Chegg, Coinbase Global, CrowdStrike, Dell Technologies, Fortinet, HP, Kohl's, Palo Alto Networks, Penn Entertainment, Shoals Technologies, SoFi Technologies and ZScaler.
Friday's top analyst upgrades and downgrades included American Tower, Charles Schwab, Crown Castle, DiamondRock Hospitality, DraftKings, Enphase Energy, GitLab, Interpublic Group of Companies, Juniper Networks, Philip Morris International, Shoals Technologies and Sunrun.
Monday's top analyst upgrades and downgrades included Bill.com, Boeing, Cardinal Health, Cognizant Technology Solutions, ConocoPhillips, C3.ai, Enphase Energy, Ford, International Paper, Meta Platforms, Nordstrom, Spirit Aerosystems and Upstart.
Tuesday's top analyst upgrades and downgrades included Advanced Micro Devices, Arista Networks, Biogen, CyberArk Software, Global Payments, Kanzhun, Medical Properties Trust, Meta Platforms, Nvidia and Redfin.
